Lecicarbon E Co2-Laxans Drei

Sodium hydrogen carbonate, the active ingredient in Lecicarbon E Co2-Laxans Drei, is an osmotic agent presented as a rectal formulation for use in the gastrointestinal tract. It helps to soften stool and promote evacuation in patients with constipation or who require bowel cleansing before diagnostic procedures. GNH USA supplies Lecicarbon E Co2-Laxans Drei as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lecicarbon E Co2-Laxans Drei is employed as an osmotic laxative for conditions affecting bowel evacuation. - Constipation: facilitates stool softening and promotes regular bowel movements. - Bowel preparation: clears the colon before colonoscopy, sigmoidoscopy or radiologic imaging. - Fecal impaction: assists in breaking down hardened stool to enable safe removal. - Post‑operative care: supports intestinal motility after abdominal surgery.

Lecicarbon E Co2-Laxans Drei may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Abdominal cramping or discomfort. - Flatulence or bloating. - Rectal irritation or mild burning. - Nausea. - Diarrhea. - Temporary electrolyte imbalance.

Serious or Rare Side Effects: - Severe dehydration. - Marked electrolyte disturbances (e.g., hypernatremia). - Rectal bleeding or ulceration. - Allergic reaction (rash, itching, swelling). - Severe abdominal pain. - Persistent inability to pass stool.

Before using Lecicarbon E Co2-Laxans Drei, consider the following safety measures. - Assess renal function: impaired kidneys may alter electrolyte handling. - Review electrolyte status: patients with existing imbalances need monitoring. - Avoid in active gastrointestinal bleeding: risk of exacerbating bleeding. - Use cautiously in inflammatory bowel disease: may increase irritation. - Pregnant or breastfeeding women: consult a healthcare professional before use. - Store at ambient temperature: keep below 25 °C, protect from moisture and direct sunlight.

Lecicarbon E Co2-Laxans Drei can interact with other medicines that influence fluid or electrolyte balance.

Major Interactions (Avoid): - Lithium: increased serum lithium levels may occur. - Potassium‑sparing diuretics: risk of hyperkalemia. - ACE inhibitors or ARBs: potential for enhanced electrolyte disturbances.

Moderate Interactions (Monitor Closely): - Oral antacids containing aluminum or magnesium: may reduce laxative efficacy. - Other osmotic laxatives: cumulative effect on fluid loss. - Antibiotics affecting gut flora: monitor for altered absorption.